Opus Genetics
Market cap $391M 96.7M shares (10-Q, Nov 6, 2026) × $4.05 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- OPGx-RDH12 trial start4Q 2026OPGx-RDH12 trial start, 4Q 2026, routine
- LCA5 program Ph3 start4Q 2026LCA5 program Ph3 start, 4Q 2026, routine
- OPGx-BEST1 4.5e9 vg Ph3 topline1Q 2027OPGx-BEST1 4.5e9 vg Ph3 topline, 1Q 2027, thesis-defining
- OPGx-MERTK trial start1Q 2027OPGx-MERTK trial start, 1Q 2027, routine
- OPGx-BEST1 first dosing Ph3 start2H 2027OPGx-BEST1 first dosing Ph3 start, 2H 2027, notable
- OPGx-RHO trial start2H 2027OPGx-RHO trial start, 2H 2027, routine
- OPGx-LCA5 corporate updateMar 31, 2028OPGx-LCA5 corporate update, Mar 31, 2028, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (12 active programs)
OPGx-BEST1
OPGx-RHO
OPGx-RDH12
OPGx-MERTK
OPGx-NMNAT1
OPGx-CNGB1
RYZUMVI
phentolamine ophthalmic solution 0.75% · phentolamine mesylate · PS- Pharmacologically Induced Mydriasis
RYZUMVI
phentolamine ophthalmic solution 0.75% · PSRYZUMVI
phentolamine ophthalmic solution 0.75%- Vision Disturbances After Keratorefractive Surgery
APX3330
Capital (as filed)
- Cash
- $89.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$14.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $89.0M cash, runway into 2029 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-08-07 S-3 · Shelf registration up to $300M aggregate
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (9)
- 2026-11-11 UPDATE: Opus Genetics (IRD) - The Warrant Overhang Clears 🔒 Paid
- 2026-10-30 UPDATE: Opus Genetics (IRD) - Half the Seat Is Filled 🔒 Paid
- 2026-10-22 UPDATE: Opus Genetics (IRD) - One Door Opens, Another Closes 🔒 Paid
- 2026-10-16 UPDATE: Opus Genetics (IRD) - The Fine Print Arrives ★ Distilled Pro
- 2026-09-09 UPDATE: Opus Genetics (IRD) - The Sentinel Was a Signal 🔒 Paid
- 2026-09-03 UPDATE: Opus Genetics (IRD) - Wednesday, 8:00 a.m. ET 🔒 Paid
- 2026-08-07 UPDATE: Opus Genetics (IRD) - The September Date Is Back On 🔒 Paid
- 2026-08-04 UPDATE: Opus Genetics (IRD) - The Registrational Trial Is Full 🔒 Paid
- 2026-06-17 Opus Genetics (IRD) — Scientific Deep Dive for OPGx-LCA5, OPGx-BEST1, and the IRD Gene Therapy Pipeline 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (9 calls)
Every verdict Biotech Distilled has published on Opus Genetics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-06-17 Watch Opus Genetics (IRD) — Scientific Deep Dive for OPGx-LCA5, OPGx-BEST1, and the IRD Gene Therapy Pipeline Genuine mechanism-backed clinical signal and elite shareholder register, but ultra-orphan commercial math, N=6/N=1 datasets, pending composition-of-matter on lead asset, and warrant-and-debt-heavy balance sheet leave risk/reward balanced after a 7x run — wait for September 2026 BEST1 Cohort 1 readout.
- 2026-08-04 Speculative buy speculative UPDATE: Opus Genetics (IRD) - The Registrational Trial Is Full Enrollment risk on the registrational LCA5 Phase 3 is retired, the RDEP framework produced an FDA-aligned design with BLA gated to six-month data, and at $3.64 the price is lower than the June watch-list level with the BEST1 readout still ahead — a starter position sized to catalyst risk is warranted.
- 2026-08-07 Speculative buy speculative UPDATE: Opus Genetics (IRD) - The September Date Is Back On September BEST1 date confirmed, LCA5 Phase 3 primary endpoint is public and objective, Phase 3 supply from commercial process retires CMC risk, and $88.8M cash covers both near-term catalysts — speculative buy maintained with no change in conviction.
- 2026-09-03 Speculative buy speculative UPDATE: Opus Genetics (IRD) - Wednesday, 8:00 a.m. ET BEST1 readout date is now fixed for September 9 with a hard timestamp, but a 19.6% pre-catalyst run has narrowed the risk/reward; speculative buy maintained for existing holders while new entrants face a materially worse trade at $4.45.
- 2026-09-09 Hold UPDATE: Opus Genetics (IRD) - The Sentinel Was a Signal BEST1 Cohort 1 delivered clean safety, structural response in 4/5, and an FDA-aligned pivotal endpoint, meaningfully retiring clinical risk, but the stock surged 54% in five weeks and the price took the payment on the same day the data arrived — hold rather than chase.
- 2026-10-16 Hold UPDATE: Opus Genetics (IRD) - The Fine Print Arrives Retina in Rio granular data shows BEST1 microperimetry responses real but thin (3.1–3.5 dB, just above the 3 dB FDA bar), while LCA5 adult durability extends to 24 months — hold because LCA5 de-risked further even though BEST1 fine print reads more like an endpoint-design exercise than a clean efficacy win.
- 2026-10-22 Hold UPDATE: Opus Genetics (IRD) - One Door Opens, Another Closes RDH12 IND cleared on schedule adding a third clinical program, but the Chief Scientific and Development Officer departed weeks before LCA5 Phase 3 dosing with no successor named, adding execution risk at a sensitive moment — hold pending confirmation of first Phase 3 patient dosed.
- 2026-10-30 Hold UPDATE: Opus Genetics (IRD) - Half the Seat Is Filled Science seat refilled within eight days with an AAV vector and potency-assay specialist, slightly reducing leadership-risk discount, but the development half of the old role remains unfilled ahead of LCA5 Phase 3 dosing — hold pending confirmed first patient dosed.
- 2026-11-11 Hold UPDATE: Opus Genetics (IRD) - The Warrant Overhang Clears Most of the warrant overhang converted to equity, book equity turned positive at $38.4M, the Oberland down-round ratchet expired unused, and BEST1 Cohort 2 readout moved up to Q1 2027 — balance-sheet bear points largely retired, but hold pending confirmed LCA5 Phase 3 first dosing.
- Long call · opened Aug 4, 2026 at $3.71 · +9.2% vs XBI -4.3% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (8 quotes from 4 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Dosing in Cohort 2 has been completed, and we expect to report topline data in the first quarter of 2027, including 3 month data for Cohort 2 participants and 6 month data for the three Cohort 1 participants with BVMD.”
matched to OPGx-BEST1 (BIRD-1 Cohort 2, 4.5e9 vg/eye) · topline data
-
-
-
“We expect to announce three-month topline data from Cohort 1 during the second week of September 2026, assuming all participants complete their assessments as scheduled.”
matched to OPGx-BEST1 · topline data -
“In February 2026, the FDA accepted the sNDA and set a Prescription Drug User Fee Act (PDUFA) action date of October 17, 2026.”
matched to OPGx-BEST1 (BIRD-1 Cohort 2, 4.5e9 vg/eye) · topline data
-
-
-
“Enrollment was completed in Cohort 1 of the Phase 1/2 trial (BIRD-1), with 3-month topline data from Cohort 1 expected during the second week of September 2026, assuming all participants complete their assessments as scheduled.”
matched to OPGx-BEST1 · topline data
-
-
-
“We expect to announce three-month topline data from Cohort 1 during the second week of September 2026, assuming all participants complete their assessments as scheduled.”
matched to OPGx-BEST1 · topline data -
“Enrollment was completed in Cohort 1 of the Phase 1/2 trial (BIRD-1), with 3-month topline data from Cohort 1 expected during the second week of September 2026, assuming all participants complete their assessments as scheduled.”
matched to OPGx-BEST1 · topline data -
“The OPGx-RDH12 program is expected to enter the clinic in the fourth quarter of 2026 and is partially funded through a partnership with the RDH12 Alliance.”
matched to OPGx-RDH12 · trial initiation -
“In February 2026, the FDA accepted the sNDA and set a Prescription Drug User Fee Act (PDUFA) action date of October 17, 2026.”
matched to Phentolamine Ophthalmic Solution 0.75% (PS) · regulatory decision · since happened Oct 16, 2026
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (37)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 3, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 10, 2026ReleaseOpus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update→ BD updateSummary on the 8-K
- Nov 10, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThe Q3 10-Q reveals the warrant overhang I've called the structural bear case nearly evaporated — 18.5M warrants exercised in Q3, only 2.86M remain and all are called — while CEO Magrath terminated his sell plan the day after the BEST1 print and the down-round ratchet expired unused, materially changing the balance-sheet and insider-signal picture ahead of the Q1 2027 Cohort 2 readout.
- Nov 10, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 5, 2026ReleaseOpus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
- Nov 3, 2026ReleaseOpus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
- Oct 29, 2026ReleaseOpus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations→ BD update
- Oct 21, 2026ReleaseOpus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness→ BD updateSummary on the 8-K
- Oct 21, 20268-KCurrent report: officer / director change→ BD updateOpus's third gene therapy just cleared the FDA's IND hurdle and will dose its first patient this quarter — but the same day, the Chief Scientific and Development Officer quietly walked out the door.
- Oct 16, 2026ReleaseOpus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaBD extracted 1 program update from this document → IRD pipeline
- Oct 15, 2026ReleaseOpus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026→ BD updateSummary on the 8-K
- Oct 15, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1→ BD updateThe Retina in Rio presentations delivered the granular structure-function data I told readers to watch for after September 9 — EZ-to-RPE thickness moved in all three evaluable BEST1 participants, pediatric LCA5 patients showed cone sensitivity reaching normal ranges, and Cohort 2 now has 11 participants. Meanwhile the stock has drifted -29% from the post-readout high to $4.05, creating a fresh entry question.BD extracted 2 program updates from this document → IRD pipeline
- Oct 13, 2026ReleaseOpus Genetics to Present at the Chardan Annual Healthcare Conference
- Sep 11, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1BD extracted 1 program update from this document → IRD pipeline
- Sep 9, 2026ReleaseOpus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027→ BD update
- Sep 9, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1→ BD updateBD extracted 1 program update from this document → IRD pipeline
- Sep 2, 2026ReleaseOpus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences→ BD updateThe BEST1 Cohort 1 topline data — the binary I've been flagging since the original deep dive — drops September 9 at 8 a.m. ET. Here's what to watch for and how to read the print when it lands.BD extracted 1 program update from this document → IRD pipeline
- Aug 7, 2026S-3Shelf registration
- Aug 6, 2026ReleaseOpus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate UpdateBD extracted 3 program updates from this document → IRD pipeline
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1
- Aug 6, 202610-QQuarterly report
- Aug 3, 2026ReleaseOpus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal DiseaseBD extracted 1 program update from this document → IRD pipeline
- Jun 17, 2026424B2Prospectus supplement
- Jun 16, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Jun 16, 20268-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Jun 5, 2026S-3Shelf registration
- May 20, 2026SCHEDULE 13D/A13D amendment
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- Apr 24, 20268-KCurrent report: debt / obligation
- Apr 22, 20268-KCurrent report: shareholder vote
- Apr 21, 2026S-3/AShelf registration (amended)
- Apr 7, 20268-KCurrent report: officer / director change
- Apr 7, 20268-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Mar 23, 2026DEF 14AProxy statement
- Mar 13, 2026S-3Shelf registration
- Mar 12, 202610-KAnnual report
- Mar 10, 20268-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
28 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13GPassive >5% holder (13G)
- Nov 16, 2026SCHEDULE 13GPassive >5% holder (13G)
- Nov 12, 2026SCHEDULE 13G/A13G amendment
- Oct 27, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026EFFECTRegistration effective
- Aug 13, 2026CORRESPCORRESP
- Aug 12, 2026UPLOADUPLOAD
- Jun 15, 2026EFFECTRegistration effective
- Jun 11, 2026CORRESPCORRESP
- Jun 10, 2026UPLOADUPLOAD
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 14, 2026S-8Employee plan registration
- May 13, 2026SCHEDULE 13G/A13G amendment
- May 13, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 22, 2026EFFECTRegistration effective
- Apr 21, 2026CORRESPCORRESP
- Mar 23, 2026ARSAnnual report to shareholders
- Mar 17, 2026UPLOADUPLOAD
- Mar 12, 2026PRE 14APRE 14A